Company: CERO
Filing Date: 2025-01-21
Form Type: S-1/A
Source: 0001213900-25-004742
Chunk: 137

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-01-21
Form: S-1/A
Chunk 137
---
 reflecting a redemption price of $11.11 per share. |

| B. | Reflects                                                                                                                         
 the reclassification of PBAX’s remaining 82,047 shares from redeemable to permanent equity and reclassification of the remaining 
 $911,357 from the restricted cash held in trust to cash.                                                                         |

| C. | Reflects                                                                                                                               
 the automatic conversion of $605,230 of principal and $27,636 of accrued interest into 631 shares of Series A Preferred Stock based on 
 the final terms of the Bridge Financing. This adjustment includes a $5,538 adjustment to retained earnings to reflect the amortization 
 of the remaining debt discount and $2,096 of derivative liabilities associated with the Preferred A conversion features.               |

| D. | Reflects                                                                                                                                    
 the elimination of Legacy CERo’s outstanding equity, exclusive of its preferred shares which is adjusted in (E), comprised of 9,068,899     
 shares of common stock, par value of $0.0001, accumulated deficit of $43,089,821, and a $43,088,914 decrease in additional paid-in capital. |

81

| E. | Reflects                                                                                                                                        
 the Merger Consideration (as defined in the Business Combination Agreement), including the estimated fair value of shares of Class A            
 Common Stock to existing Legacy CERo common stock shareholders, estimated fair value of 4,415,494 shares of Class A Common Stock to existing    
 convertible preferred shareholders (Note 3), estimated fair value of 875,000 shares of Class A Common Stock to existing shareholders            
 for reallocation shares, estimated fair value of 2,200,000 shares of Class A Common Stock to existing shareholders for earnout and reallocation 
 shares, and estimated transaction costs. Also reflects the elimination of Legacy CERo’s Series Seed preferred stock and Series                  
 A preferred stock at $4,077,560 and $38,023,784, respectively, an increase in additional paid-in capital of $87,819,313, as well as the         
 adjustment to accumulated deficit for the acquired IPR&D as follows:                                                                            |

|                                                              |     | December 31, 
 2023         |            |   |
|:-------------------------------------------------------------|:----|:-------------|-----------:|:--|
| Expensed IPR&D acquired (DD)                                 |     |              | 45,101,193 |   |
| Long-term assets                                             |     |              |  3,156,267